Engflag

Nalixone

Quick links to important sections

Nalixone

Nalixone_ES

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nalixone

Nalixone is defined as a fixed-dose combination pharmaceutical preparation for oral administration that integrates two active components to address both the microbial cause and the immediate symptoms of lower urinary tract irritation.

Property Description
Active ingredient Nalidixic Acid, Phenazopyridine
Form Oral Solid Dosage Form (Tablet)
Pharmacological Class Quinolone Antibacterial, Urinary Tract Analgesic
General Purpose Simultaneous infection control and symptom relief
Origin Synthetic Organic Compound

What is Nalixone and What Type of Medicine is It?

Nalixone is classified as both a urinary tract anti-infective and a urinary tract analgesic, a dual classification reflecting the necessary roles of its two main ingredients in treating acute, uncomplicated urinary tract symptoms. The medicine contains Nalidixic Acid, which belongs to the class of synthetic quinolone antibiotics, and Phenazopyridine, which is a local anesthetic compound. Nalidixic Acid is clinically recognized for its efficacy against a range of susceptible Gram-negative bacteria, demonstrating a bactericidal action by interfering with microbial DNA replication.

What is the Composition and Dual Purpose of Nalixone?

The medicine’s composition is engineered for simultaneous support. Nalidixic Acid provides the necessary anti-infective action against microbial populations, while Phenazopyridine, which is chemically an azo dye, delivers symptomatic relief. The latter component exerts a localized anesthetic effect directly on the urinary tract mucosa. The general purpose of this combination is comprehensive: to offer rapid, localized relief from discomforts like burning and urgency while the anti-infective action begins the work of microbial elimination. This dual functionality is the primary therapeutic benefit over single-component agents.

How Does Nalixone Differ from Single-Ingredient Drugs?

Nalixone's fixed-dose combination form is its distinguishing feature. Unlike using a sole quinolone antibiotic which would only manage the infection, or a solitary urinary tract analgesic which only manages pain, this medicine delivers both the necessary microbial management and the immediate local anesthetic effect concurrently. This integrated approach ensures that the patient receives a coordinated therapeutic strategy against both the microbial threat and the discomfort associated with irritation in a single oral solid dosage form.

Regulatory References

  1. Phenazopyridine - NIH

What side effects are possible with Nalixone?

The official safety profile for Nalixone's components (Nalidixic Acid and Phenazopyridine) is categorized by government regulatory agencies into systems and frequencies.

Adverse Reaction Scope

The most common adverse reactions reported include gastrointestinal disturbance (nausea, vomiting, diarrhea) and Nervous System effects like headache and dizziness. An expected, non-toxic characteristic of the Phenazopyridine component is the reddish-orange discoloration of urine and potential staining of contact lenses.

System-Organ Class Examples of Documented Reactions
Nervous System Disorders Headache, dizziness, visual disturbances, toxic psychosis, and rarely, convulsive seizures or intracranial hypertension (pseudotumor cerebri).
Skin & Hypersensitivity Rash, itching, and potential for photosensitivity reactions upon sun exposure. Rarely, severe anaphylactoid reactions are documented.
Blood and Lymphatic Hemolytic anemia, methemoglobinemia, leukopenia, and thrombocytopenia, sometimes associated with specific pre-existing conditions.
Gastrointestinal Disorders Nausea, vomiting, abdominal pain, diarrhea.
Musculoskeletal Tendon effects, including tendon rupture, a serious adverse reaction associated with the quinolone class.

Safety Constraints and Special Populations

Explicit safety constraints define the appropriate use of the medicine's components. Nalidixic Acid is contraindicated in infants less than three months of age and in patients with a history of convulsive disorders or porphyria. Patients with G6PD deficiency are at an increased risk of hemolytic anemia. Severe renal insufficiency and severe liver disease are regulatory limitations for the medicine's use due to the risk of component accumulation and toxicity.

Contextual Safety Notes

Regulatory information notes that some effects, such as visual changes and intracranial hypertension, have generally been reported to resolve upon discontinuation of the medicine. The risk of photosensitivity is directly related to sun exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Nalixone overdose addresses combined toxicities from both active components. Emergency medical attention must be sought immediately in all suspected overdose cases. Contact a Poison Control Center right away or call emergency services if symptoms include collapse, seizures, or severe difficulty breathing.

Documented Overdose Manifestations

Overdose presentation involves effects on the Central Nervous System (CNS) and the Hematological System. CNS effects, primarily associated with the Nalidixic Acid component, include toxic psychosis, convulsions, and documented increases in intracranial pressure. Systemic toxicity, linked to the Phenazopyridine component, may manifest as methemoglobinemia, oxidative hemolytic anemia, and signs of drug accumulation such as a yellowish tinge to the skin or sclera (jaundice). Severe outcomes include metabolic acidosis and potential hepatic or renal failure.

Management and Population Considerations

If overdose occurs, symptomatic and supportive treatment must be instituted. A specific intervention with Methylene blue or Ascorbic acid is documented for the management of methemoglobinemia. Monitoring may require testing of blood methemoglobin levels and kidney function. Elderly patients are noted to be at increased risk of toxic reactions due to potential drug accumulation.

Therapeutic Uses of Nalixone

What Nalixone Treats: Main Uses and Benefits

Therapeutic Scope and Benefits

The therapeutic benefit of Nalixone is defined by its two-pronged approach, which is used for managing both the microbial cause of the symptoms and the patient's acute discomfort in clinical scenarios. This medication is commonly used in conditions characterized by acute, uncomplicated lower urinary tract infections (UTIs), such as cystitis and urethritis.

The anti-infective support is relevant for managing the proliferation of pathogens and contributes to the process of microbial clearance relevant in conditions where functional stability becomes affected. The analgesic component provides supportive symptomatic relief, which is applied in contexts where patients experience pronounced, distressing urinary symptoms that create noticeable interference with daily stability. The medication's role is generally to provide supportive relief during the acute, symptomatic phase.

Quick Fact: Relief for Acute Urinary Discomfort

The medicine assists with managing irritative voiding symptoms, providing localized support for the burning and urgency often associated with active infection.

Eligibility and Restrictions for Use

The eligibility profile for Nalixone is strictly defined by regulatory authorities and centers on patient health status and age. The medicine is contraindicated and must not be used by patients with renal insufficiency or severe liver disease, as the drug components can rapidly accumulate and lead to toxicity. Absolute contraindications also apply to individuals with a history of convulsive disorders (including epilepsy) or porphyria. The medicine is prohibited for use in infants less than 3 months of age.

Use is restricted and requires special consideration in several populations. These restrictions include prepubertal children, due to the potential for arthropathy, and older adults, where declining renal function mandates caution. For pregnancy, use is severely restricted and contraindicated in pyelonephritis of pregnancy. Additionally, the medicine is not recommended for women who are breastfeeding due to the components being excreted in human milk. Patients with specific conditions like G6PD deficiency or known CNS disorders must also be evaluated with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nalixone, a fixed-dose combination of Nalidixic Acid and Phenazopyridine, has officially documented interaction patterns that establish constraints on co-administration with other substances and medical conditions.

Contraindications and Exposure Management

Co-administration with Melphalan or related cancer chemotherapeutic alkylating agents is formally contraindicated due to the documented risk of severe gastrointestinal toxicity. The Phenazopyridine component is also contraindicated in renal insufficiency and severe liver disease/hepatitis because of the risk of drug accumulation caused by impaired clearance.

Pharmacokinetic and Pharmacodynamic Interactions

The Nalidixic Acid component may enhance the effects of Oral Anticoagulants like Warfarin, requiring close monitoring of coagulation indicators. It also inhibits the metabolism of other drugs, resulting in elevated plasma levels of co-administered Theophylline and reduced clearance of Caffeine. Furthermore, Nitrofurantoin is documented to interfere with the therapeutic action of Nalidixic Acid.

Timing and Product Interference

Certain products substantially interfere with Nalixone's absorption, leading to lower systemic levels. Products containing divalent or trivalent cations—such as Antacids (containing Aluminum, Magnesium, or Calcium), Sucralfate, and supplements containing Iron or Zinc—must not be taken within the two-hour period before or after Nalixone administration. Additionally, the azo dye in the medicine may interfere with laboratory results, specifically colorimetric urinalysis tests for substances like glucose or ketone.

Mechanism of Action

Naloxone functions as a pure, competitive opioid receptor antagonist, exhibiting its highest binding affinity for the mu-opioid receptor (MOR) within the central nervous system (CNS). It also antagonizes kappa- and delta-opioid receptors, although with lower potency. Naloxone competitively binds to these receptor sites, displacing any occupied opioid agonists due to its higher binding affinity.

At the intracellular level, mu-opioid receptors are G-protein coupled receptors typically coupled to Gi/Go proteins. Agonist binding normally activates the Gi subunit, which subsequently inhibits the enzyme adenylate cyclase. This inhibition reduces the synthesis of the intracellular second messenger cyclic adenosine monophosphate (cAMP), leading to reduced neuronal excitability.

As a competitive antagonist, Naloxone blocks opioid agonists from initiating this Gi-protein cascade. This blockade prevents the opioid-induced inhibition of adenylate cyclase, thereby facilitating the restoration of normal cAMP levels and re-establishing typical neuronal signaling rates in key CNS regions, particularly the brainstem. The resulting system-level physiological consequence is the modulation of respiratory drive and level of consciousness due to the rapid removal of opioid-mediated inhibitory signaling.

Dosage and Administration Information

How Nalixone is Used in Clinical Practice

Nalixone is a fixed-dose combination medicine that requires a two-phase administration structure based on the pharmacological profiles of its two active components, Nalidixic Acid and Phenazopyridine.

Official Administration and Dosing

The medicine is administered orally in an Oral Solid Dosage Form. The use protocol is defined by the need to address both acute symptoms and the underlying infection:

Feature Official Usage Principle
Dosing Frequency Typically administered three to four times daily (TID to QID) during the initial phase.
Intake Context Must be taken with or immediately following food or a snack and swallowed with a full glass of water to help prevent gastrointestinal upset. Co-administration with antacids is to be avoided.

Duration Protocol and Constraints

The treatment duration is governed by the analgesic component, Phenazopyridine. The overall regimen follows this distinct procedural structure:

  • Initial Dual-Phase: Concomitant use of the anti-infective and analgesic components is limited to a maximum of 2 days (48 hours).
  • Maintenance Phase: The anti-infective component (Nalidixic Acid) must be continued alone after the initial two days to complete the course, which typically lasts for 7 to 14 days.

Population-Specific Constraint: The analgesic component is contraindicated in renal insufficiency, a principle that guides the use of the combination medicine in patients with kidney impairment. For the anti-infective component alone, the dosage must be reduced by half if the patient's creatinine clearance is le 20 mL/min.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nalixone

Evidence for Use in Acute, Uncomplicated Lower UTIs

Research was studied for its use in a combination of two components in conditions associated with acute or disruptive episodes, specifically uncomplicated lower urinary tract infections (UTIs) where outcomes related to physical discomfort are noticeable. Studies have been conducted during periods of increased symptom activity to monitor how the individual components were studied. The evidence base includes Randomized Controlled Trials (RCTs) focusing on the main anti-infective component, along with Systematic Reviews that analyze studies where it was evaluated in comparison to other anti-bacterial treatments, and specific trials for the analgesic component.

These studies research examined two types of outcomes: bacteriological cure (checking for microbial clearance) and patient-reported outcomes describing perceived discomfort. The research focused on populations consisting mainly of adult female outpatients (typically aged 16 to 65 years) whose UTI status was often confirmed by laboratory culture. Findings describe patterns observed in the studies over defined time intervals, contributing to the broader evidence landscape related to microbial clearance and how patients reported their experience with their symptoms.

The Dual Approach: Antibacterial and Symptomatic Evidence

The research explored the two distinct roles of Nalixone within a single treatment course. Evidence was evaluated in trials where researchers monitored the anti-infective component’s ability to address microbial presence. Separately, studies focusing on the analgesic component explored short-term symptom changes in outcomes related to physical discomfort, such as pain, burning, and urgency. These studies were conducted during periods of increased symptom activity to examine changes in outcomes linked to inflammatory or irritative states.

Research highlights changes measured during the study period for both microbial clearance and symptomatic outcomes. Studies report how symptoms evolved in the observed populations, with specific attention paid to the time elapsed until initial symptom improvement was documented. These short-term symptomatic endpoints were typically assessed within the first 24 to 72 hours of the study period.

Frequently Asked Questions (FAQ)

Common questions about Nalixone (FAQ)

Q: How is the risk of allergic reaction described in official information for Nalixone?

A: Official documents describe the potential for skin reactions, such as rash and itching, as part of the safety profile. Rarely, severe reactions described as anaphylactoid reactions are documented. Severe reactions are noted within the adverse event scope.

Q: Is there official guidance on using Nalixone while breastfeeding?

A: According to the official product information, components of Nalixone are described as being excreted into human milk. Due to potential risks, the medicine is generally not recommended while breastfeeding, especially when the infant has a condition called G6PD deficiency, due to the potential risk of hemolytic anemia.

Q: Does Nalixone affect the results of drug screenings or urine tests?

A: Yes, the azo dye component of Nalixone is known to potentially interfere with the results of certain laboratory tests. Specifically, this interference affects colorimetric urinalysis tests used to check for substances like glucose or ketone.

Q: What information exists about using Nalixone in elderly populations?

A: Official guidance indicates that caution is mandated when using Nalixone in older adults. This is because age-related decline in renal function may occur, which could increase the risk of the drug components accumulating in the body.

Q: What is the explanation for why Nalixone is not considered a controlled substance?

A: Nalixone is not classified as a controlled substance. Official records from government regulatory authorities state that its active components, Nalidixic Acid and Phenazopyridine, are not scheduled under federal drug laws.

Q: How are the risks and benefits of using Nalixone described for pregnant individuals?

A: Regulatory documents state that use is severely restricted during pregnancy and is explicitly contraindicated, or prohibited, in cases of pyelonephritis of pregnancy (a severe kidney infection). The anti-infective component is assigned to Pregnancy Category C.

Q: What is the official guidance on patient monitoring after Nalixone is administered?

A: Official guidance for the anti-infective component recommends periodic monitoring of several factors. This includes monitoring blood counts, liver function tests, and renal function tests when therapy extends beyond two weeks.

Q: How long is the effect of Nalixone generally understood to last in the body?

A: The duration of effect is understood to differ between the two components of the medicine. The analgesic (pain-relieving) component provides local symptomatic relief for a relatively shorter period, while the anti-infective component has an average half-life described as 8 to 10 hours.

Q: Are there known or reported interactions with herbal supplements and Nalixone?

A: Official warnings mention that the anti-infective component can interact with common substances like caffeine (found in some supplements and herbs). Additionally, the absorption of the medicine can be reduced by supplements containing minerals such as iron or zinc.

Q: What are the common signs of a medical emergency that indicate Nalixone may be needed?

A: The medicine is officially indicated for use during conditions associated with symptoms such as pain, burning sensation during urination, urgency, and irritation. These are the symptoms of acute, uncomplicated lower urinary tract infections.

Q: What research findings available regarding the effectiveness of multiple doses of Nalixone?

A: Regulatory instructions define a necessary multiple-dose regimen for the initial treatment phase. Research evidence was gathered to monitor efficacy and microbial clearance themes over defined study periods in which patients received multiple doses of the medicine.

Q: What research has been conducted on the psychological effects following Nalixone administration?

A: The adverse reactions section of the official documents lists specific nervous system and psychiatric effects. These include toxic psychosis (a mental disturbance), visual disturbances, and dizziness.

Q: How does the administration method affect the onset of Nalixone's action?

A: Official guidelines describe the medicine as being taken with or immediately following food to help prevent gastrointestinal upset. The analgesic component is described separately as providing rapid, local relief in the urinary tract shortly after administration.

How should Nalixone be stored and disposed of?

How to Store and Dispose of Nalixone?

The storage of Nalixone (Nalidixic Acid and Phenazopyridine) tablets must strictly follow regulatory requirements to maintain product stability.

Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature (20 C to 25 C, 68 F to 77 F)
Protection Protect from excessive heat and excessive moisture
Container Must be kept in a tightly closed container

Handling and Disposal

Storage must always be out of the reach of children.

Disposal of unused or expired tablets should be done via a drug take-back program or as directed by a healthcare professional. Disposal should align with local regulations and generally avoid flushing or discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nalixone found in:

A-Z Index: